(Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.)
I go back a long way with the diabetes space, and glucose monitoring in particular, as that was a big part of my coverage group back in the sell-side research days. During that time, there was the occasional MiniMed (acquired by Medtronic (NYSE:MDT)) or TheraSense (acquired by Abbott Labs (NYSE:ABT)), but quite a few Integs for every one of those successes. Today, Echo Therapeutics (NASDAQ:ECTE) is grinding along, hoping that its Symphony tCGM System vaults it into the winner's circle with...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|